SLC22A17 and cancer: For instance, the decrease of SLC22A17 inhibits iron efflux from cancer cells resulting in iron-dependent proliferation (Hvidberg et al., 2005; Iannetti et al., 2008) and resistance to apoptosis (Devireddy et al., 2005).